<DOC>
	<DOCNO>NCT01861314</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bortezomib sorafenib tosylate give together decitabine treat patient acute myeloid leukemia . Bortezomib sorafenib tosylate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving bortezomib sorafenib tosylate together decitabine may work well treat acute myeloid leukemia .</brief_summary>
	<brief_title>Bortezomib , Sorafenib Tosylate , Decitabine Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To identify biologically effective tolerable dose ( BETD ) bortezomib/sorafenib ( sorafenib tosylate ) combination acute myeloid leukemia ( AML ) biological activity define dose ( ) induce 100 % increase ( i.e . double ) level microRNA-29b ( miR-29b ) bone marrow ( BM ) bortezomib/sorafenib treatment pretreatment level least 5 6 patient give dose level . II . To recommend dose level Phase II study use agent combination patient AML . III . To define specific toxicity dose limit toxicity ( DLT ) bortezomib combination sorafenib decitabine . SECONDARY OBJECTIVES : I . To determine overall response rate ( ORR ) combination . II . To determine rate complete remission ( CR ) combination . III . To conduct pharmacodynamic study measure effect chemotherapy combination micronome , kinome epigenome . OUTLINE : This dose-escalation study bortezomib sorafenib tosylate . STEP A : Patients receive bortezomib subcutaneously ( SC ) day 1 4 , sorafenib tosylate orally ( PO ) twice daily ( BID ) day 1-14 , decitabine intravenously ( IV ) 1 hour day 5-14 . STEP B : Patients receive bortezomib SC day 1 , 4 , 8 1 , 4 , 8 11 , sorafenib tosylate PO BID day 1-14 , decitabine IV 1 hour day 9-18 12-21 . STEP C : Patients receive bortezomib SC day 1 , 4 , 8 1 , 4 , 8 11 , sorafenib tosylate PO BID day 1-14 , decitabine IV 1 hour day 5-14 . Treatment repeat every 28 day 4 course absence unacceptable toxicity . Patients achieve complete response ( CR ) incomplete CR ( CRi ) receive maintenance therapy comprise decitabine IV day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologically cytologically confirm acute myeloid leukemia ( AML ) World Health Organization ( WHO ) criteria blood and/or marrow AND age &gt; = 60 candidates/refuse standard induction treatment OR one following : poor risk cytogenetics , AML follow antecedent hematologic disorder , therapyrelated AML Patients relapse refractory AML age &gt; = 18 year also eligible treatment ; patient may treat antecedent hematologic disorder myeloid growth factor , recombinant erythropoietin , thalidomide , lenalidomide , 5azacitidine 5 day schedule decitabine ; patient receive 10 day schedule decitabine treatment antecedent hematologic disorder AML eligible If patient comorbid medical illness , life expectancy attribute must great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Total bilirubin &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transferase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transferase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal Creatinine &lt; 2.0 mg/dL creatinine clearance ( CrCl ) &gt; = 60 mL/min Prothrombin time ( PT ) /international normalize ratio ( INR ) monitoring , &lt; 1.5 x institutional upper limit normal Both woman men must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry duration study participation ; patient agree , patient eligible Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study ; hydroxyurea may administer count control pretreatment cycle 1 Patients receive investigational agent patient receive investigational agent within 14 day enrollment Patients active central nervous system disease granulocytic sarcoma sole site disease Patients history allergic reaction attribute compound similar chemical biologic composition sorafenib , bortezomib decitabine easily manage Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; infection common feature AML , patient active infection permit enroll provide infection control ; myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , uncontrolled hypertension , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Patients serious medical psychiatric illness likely interfere participation clinical study Patients preexist grade 2 high neuropathy serious neurologic toxicity would significantly increase risk complication bortezomib therapy exclude Patients know confirmed diagnosis human immunodeficiency virus ( HIV ) infection take chronic antiretroviral therapy ( HAART ) ineligible potential drugdrug interaction chemotherapeutic agent ; patient know confirmed diagnosis HIV infection meet standard eligibility criterion take HAART potential drugdrug interaction eligible Patients advance malignant solid tumor exclude Patients know impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption sorafenib Patients take concomitant medication investigator 's opinion strong inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) enzymes therefore likely interact study agent , eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>